Learn about Multaq, a prescription medicine which can help control irregular heart rhythm in patients with AFib and reduce the risk of hospital visits due to AFib. See important safety information.
On 2 July 2009, the company received approval for Multaq 400mg tablets from the US Food and Drug Administration (FDA) for use in adults who currently have or previously had non-permanent atrial fibrillation, as a means to prevent atrial fibrillation reccurence or slow down the ventricular rate...
Each tablet of MULTAQ contains 400 mg of dronedarone (expressed as base). The inactive ingredients are: Core of the tablets: Colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, poloxamer 407, starch. Coating/polishing of the tablets: Carnauba wax, hypromell...